* Histogen Inc HSTO.OQ HSTO.O is expected to show a fall
in
quarterly revenue when it reports results on November 8
(estimated).
*
* Refinitiv's mean analyst estimate for Histogen Inc is for
a
loss of $1.26 per share.
* The one available analyst rating on the shares is "strong
buy".
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Histogen
Inc is
$17.5, above its last closing price of $1.11.
This summary was machine generated November 5 at 03:05 GMT. All
figures in US dollars unless otherwise stated